Mesenchymal stroma: Role in osteosarcoma progression

被引:123
作者
Cortini, Margherita [1 ,2 ]
Avnet, Sofia [1 ]
Baldini, Nicola [1 ,2 ]
机构
[1] Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Via Barbiano 1-10, I-40136 Bologna, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
关键词
Mesenchymal stroma; Osteosarcoma; Microenvironment; IL-6; Extracellular vesicles; Metabolites; CELLS PROMOTE GROWTH; STEM-CELLS; TUMOR-STROMA; HUMAN BONE; OSTEOGENIC DIFFERENTIATION; MYOFIBROBLASTS CONTRIBUTE; PROGNOSTIC BIOMARKER; SIGNAL TRANSDUCER; GENE-EXPRESSION; IN-VIVO;
D O I
10.1016/j.canlet.2017.07.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The initiation and progression of malignant tumors are supported by their microenvironment: cancer cells per se cannot explain growth and formation of the primary or metastasis, and a combination of proliferating tumor cells, cancer stem cells, immune cells mesenchymal stromal cells and/or cancer-associated fibroblasts all contribute to the tumor bulk. The interaction between these multiple players, under different microenvironmental conditions of biochemical and physical stimuli (i.e. oxygen tension, pH, matrix mechanics), regulates the production and biological activity of several soluble factors, extracellular matrix components, and extracellular vesicles that are needed for growth, maintenance, chemoresistance and metastatization of cancer. In osteosarcoma, a very aggressive cancer of young adults characterized by the extensive need for more effective therapies, this aspect has been only recently explored. In this view, we will discuss the role of stroma, with a particular focus on the mesenchymal stroma, contributing to osteosarcoma progression through inherent features for homing, neo-vascularization, paracrine cross-feeding, microvesicle secretion, and immune modulation, and also by responding to the changes of the microenvironment that are induced by tumor cells. The most recent advances in the molecular cues triggered by cytokines, soluble factors, and metabolites that are partially beginning to unravel the axis between stromal elements of mesenchymal origin and osteosarcoma cells, will be reviewed providing insights likely to be used for novel therapeutic approaches against sarcomas. (c) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:90 / 99
页数:10
相关论文
共 149 条
  • [1] Do Mesenchymal Stromal Cells Influence Microscopic Residual or Metastatic Osteosarcoma in a Murine Model?
    Aanstoos, Megan E.
    Regan, Daniel P.
    Rose, Ruth J.
    Chubb, Laura S.
    Ehrhart, Nicole P.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2016, 474 (03) : 707 - 715
  • [2] Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies
    Abarrategi, Ander
    Tornin, Juan
    Martinez-Cruzado, Lucia
    Hamilton, Ashley
    Martinez-Campos, Enrique
    Rodrigo, Juan P.
    Victoria Gonzalez, M.
    Baldini, Nicola
    Garcia-Castro, Javier
    Rodriguez, Rene
    [J]. STEM CELLS INTERNATIONAL, 2016, 2016
  • [3] CD117 and Stro-1 Identify Osteosarcoma Tumor-Initiating Cells Associated with Metastasis and Drug Resistance
    Adhikari, Amit S.
    Agarwal, Neeraj
    Wood, Byron M.
    Porretta, Constance
    Ruiz, Bernardo
    Pochampally, Radhika R.
    Iwakuma, Tomoo
    [J]. CANCER RESEARCH, 2010, 70 (11) : 4602 - 4612
  • [4] Bone microenvironment signals in osteosarcoma development
    Alfranca, Arantzazu
    Martinez-Cruzado, Lucia
    Tornin, Juan
    Abarrategi, Ander
    Amaral, Teresa
    de Alava, Enrique
    Menendez, Pablo
    Garcia-Castro, Javier
    Rodriguez, Rene
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (16) : 3097 - 3113
  • [5] Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation
    Avnet, Sofia
    Di Pompo, Gemma
    Chano, Tokuhiro
    Errani, Costantino
    Ibrahim-Hashim, Arig
    Gillies, Robert J.
    Donati, Davide Maria
    Baldini, Nicola
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (06) : 1331 - 1345
  • [6] Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance
    Avnet, Sofia
    Lemma, Silvia
    Cortini, Margherita
    Pellegrini, Paola
    Perut, Francesca
    Zini, Nicoletta
    Kusuzaki, Katsuyuki
    Chano, Tokuhiro
    Grisendi, Giulia
    Dominici, Massimo
    De Milito, Angelo
    Baldini, Nicola
    [J]. ONCOTARGET, 2016, 7 (39) : 63408 - 63423
  • [7] Insulin receptor isoforms are differently expressed during human osteoblastogenesis
    Avnet, Sofia
    Perut, Francesca
    Salerno, Manuela
    Sciacca, Laura
    Baldini, Nicola
    [J]. DIFFERENTIATION, 2012, 83 (05) : 242 - 248
  • [8] Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma
    Avnet, Sofia
    Sciacca, Laura
    Salerno, Manuela
    Gancitano, Giovanni
    Cassarino, Maria Francesca
    Longhi, Alessandra
    Zakikhani, Mahvash
    Carboni, Joan M.
    Gottardis, Marco
    Giuti, Armando
    Pollak, Michael
    Vigneri, Riccardo
    Baldini, Nicola
    [J]. CANCER RESEARCH, 2009, 69 (06) : 2443 - 2452
  • [9] Increased osteoclast activity is associated with aggressiveness of osteosarcoma
    Avnet, Sofia
    Longhi, Alessandra
    Salerno, Manuela
    Halleen, Jussi M.
    Perut, Francesca
    Granchi, Donatella
    Ferrari, Stefano
    Bertoni, Franco
    Giuti, Armando
    Baldini, Nicola
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) : 1231 - 1238
  • [10] Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
    Baglio, S. Rubina
    Lagerweij, Tonny
    Perez-Lanzon, Maria
    Ho, Xuan Dung
    Leveille, Nicolas
    Melo, Sonia A.
    Cleton-Jansen, Anne-Marie
    Jordanova, Ekaterina S.
    Roncuzzi, Laura
    Greco, Michelina
    van Eijndhoven, Monique A. J.
    Grisendi, Giulia
    Dominici, Massimo
    Bonafede, Roberta
    Lougheed, Sinead M.
    de Gruijl, Tanja D.
    Zini, Nicoletta
    Cervo, Silvia
    Steffan, Agostino
    Canzonieri, Vincenzo
    Martson, Aare
    Maasalu, Katre
    Koks, Sulev
    Wurdinger, Tom
    Baldini, Nicola
    Pegtel, D. Michiel
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3721 - 3733